National Institutes of Health: Multiple Myeloma trials

The registry lists 149 Multiple Myeloma studies with National Institutes of Health as lead sponsor. 11 are open to participants now and 69 have results posted.

Phase 1 48Phase 2 90Phase 3 10No phase 14(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
• Imaging Studies and the Development of Multiple MyelomaWithdrawnNCT01571726Phase 2
• Viral Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01533194Phase 1
• Providing Access to Cord Blood Units for TransplantsWithdrawnNCT01479582Phase 2
• Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1
• RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
• Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure StudyCompletedNCT01139476
• Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
• Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood DisordersTerminatedNCT00973804Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
• Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
• Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00693433Phase 1
• Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy StudiesCompletedNCT00427726
• Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
• Agriculture Health StudyActive, not recruitingNCT00352924
• Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
• Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
• Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
• Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
• Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
• Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• Temsirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00079456Phase 2
• FR901228 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00066638Phase 2
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney FailureCompletedNCT00062621Phase 1
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• Flavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00047203Phase 2
• Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
• 2-Methoxyestradiol in Treating Patients With Advanced Solid TumorsCompletedNCT00028821Phase 1
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Blood and Marrow Transplant Clinical Research NetworkCompletedNCT00023530Not applicable
• Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003853Phase 2
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple MyelomaCompletedNCT00002556Phase 3
• The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood CancersCompletedNCT00001873Phase 2
• Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsCompletedNCT00001830Phase 1
• Comparing Treatments for Multiple MyelomaCompletedNCT00001750Phase 2
• Bone Marrow Transplant Studies for Safe and Effective Treatment of LeukemiaCompletedNCT00001623Not applicable
• Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow TransplantationCompletedNCT00001561Phase 3